ECSP23034914A - Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Info

Publication number
ECSP23034914A
ECSP23034914A ECSENADI202334914A ECDI202334914A ECSP23034914A EC SP23034914 A ECSP23034914 A EC SP23034914A EC SENADI202334914 A ECSENADI202334914 A EC SENADI202334914A EC DI202334914 A ECDI202334914 A EC DI202334914A EC SP23034914 A ECSP23034914 A EC SP23034914A
Authority
EC
Ecuador
Prior art keywords
compositions
treatment
methods
eye disease
thyroid eye
Prior art date
Application number
ECSENADI202334914A
Other languages
English (en)
Inventor
Peter Harwin
Yang Zhao
Angela She
Vahe Bedian
Jonathan Violin
Tomas Kiselak
Original Assignee
Viridian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viridian Therapeutics Inc filed Critical Viridian Therapeutics Inc
Publication of ECSP23034914A publication Critical patent/ECSP23034914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y composiciones contra IGF-1R y los usos de los mismos.
ECSENADI202334914A 2020-10-14 2023-05-11 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea ECSP23034914A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063091839P 2020-10-14 2020-10-14
US202163201978P 2021-05-21 2021-05-21
US202163260130P 2021-08-10 2021-08-10
US202163261742P 2021-09-28 2021-09-28

Publications (1)

Publication Number Publication Date
ECSP23034914A true ECSP23034914A (es) 2023-06-30

Family

ID=81208791

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202334914A ECSP23034914A (es) 2020-10-14 2023-05-11 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Country Status (16)

Country Link
US (7) US20220267451A1 (es)
EP (1) EP4228616A1 (es)
JP (1) JP2023545520A (es)
KR (1) KR20230124550A (es)
AU (1) AU2021360889A1 (es)
CA (2) CA3195512A1 (es)
CL (1) CL2023001052A1 (es)
CO (1) CO2023005996A2 (es)
CR (1) CR20230204A (es)
DO (1) DOP2023000073A (es)
EC (1) ECSP23034914A (es)
IL (1) IL302068A (es)
MX (1) MX2023004280A (es)
PE (1) PE20231202A1 (es)
TW (2) TW202229350A (es)
WO (2) WO2022081799A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
WO2023019171A1 (en) * 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CA2611149A1 (en) 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
CN102481361B (zh) * 2009-04-16 2014-10-22 默沙东公司 用于治疗癌症的组合物和方法
UY32603A (es) 2009-05-01 2010-12-31 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AR083705A1 (es) 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2836560C (en) 2011-05-18 2020-06-30 University Of Florida Research Foundation, Inc. Macrocyclic therapeutic agents and methods of treatment
JP2014516964A (ja) * 2011-05-18 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 治療用抗ｉｇｆ１ｒ合剤
EP2714733B1 (en) 2011-05-21 2019-01-23 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CA2862433A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112014020304A8 (pt) 2012-02-15 2018-01-16 Ecole Polytechnique Fed Lausanne Epfl terapêutica para ligação de eritrócitos
WO2013148568A1 (en) * 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013191982A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind igf1r
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
AR112600A1 (es) 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
US11208490B2 (en) * 2018-03-05 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US20210284741A1 (en) 2018-01-24 2021-09-16 Hznp Limited Methods for the treatment of thyroid eye disease
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
JP2021529531A (ja) 2018-06-29 2021-11-04 クリスタル バイオテック インコーポレイテッド 抗体送達のための組成物及び方法
US20220127336A1 (en) * 2018-12-19 2022-04-28 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
AU2020337958A1 (en) * 2019-08-28 2022-03-17 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease

Also Published As

Publication number Publication date
EP4228616A1 (en) 2023-08-23
US20240043546A1 (en) 2024-02-08
US11548951B1 (en) 2023-01-10
WO2022081799A1 (en) 2022-04-21
DOP2023000073A (es) 2023-09-29
MX2023004280A (es) 2023-06-23
US20220275096A1 (en) 2022-09-01
US20220267450A1 (en) 2022-08-25
CO2023005996A2 (es) 2023-05-29
JP2023545520A (ja) 2023-10-30
WO2022081804A1 (en) 2022-04-21
CL2023001052A1 (es) 2023-11-17
AU2021360889A1 (en) 2023-06-15
US20230279122A1 (en) 2023-09-07
US20230002495A1 (en) 2023-01-05
CA3195512A1 (en) 2022-04-21
CA3195590A1 (en) 2022-04-21
IL302068A (en) 2023-06-01
KR20230124550A (ko) 2023-08-25
TW202229350A (zh) 2022-08-01
CR20230204A (es) 2023-10-11
PE20231202A1 (es) 2023-08-17
US20220267451A1 (en) 2022-08-25
US20220235137A1 (en) 2022-07-28
TW202228775A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
ECSP23034914A (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
AR105600A1 (es) Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos
CO2020015172A2 (es) Anticuerpos biespecíficos contra dll3-cd3
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
ECSP20078226A (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CO2017002494A2 (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2021015184A2 (es) Conjugados de anticuerpo y fármaco
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023012639A2 (es) Métodos para el tratamiento de la enfermedad ocular tiroidea
CL2019000471A1 (es) Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448)
CR20170346A (es) Composiciones para el tratamiento de infecciones producidas por el ácaro demodex spp
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
NI201800105A (es) Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares